Background
==========

Crohn's disease (CD) is a chronic inflammatory disorder that may affect the gastrointestinal tract from the mouth to the anus. Inflammation is transmural and therefore may be complicated by fistula, abscess formation, perforations, and fibrotic strictures. The disease may cause significant morbidity and diminished quality of life.[@b1-ppa-10-1043]--[@b5-ppa-10-1043] Disease behavior is characterized by periods of flare-ups with active symptomatic disease and periods of remission.[@b6-ppa-10-1043]

Imaging studies are essential in the diagnosis, treatment, and follow-up of inflammatory bowel disease (IBD) patients. The use of bowel imaging serves to confirm the diagnosis, assess disease extent and characteristics (inflammatory versus fibrostenotic), and complications.

Bowel imaging is essential during follow-up of patients with chronic disease and affects treatment strategy, medications choices and dosages, and recommendations for surgical or endoscopic interventions. Increasingly, bowel imaging is becoming a routine monitoring tool of treatment outcomes and guides further management even in patients with clinical response or mild symptoms. Overall, patients are required to undergo increasing numbers of repeated bowel imaging studies throughout their disease course.

Two of the most sensitive small bowel imaging modalities are -- magnetic resonance enterography (MRE) and small bowel capsule endoscopy (SBCE). Both modalities are radiation free. When performing MRE, examination sequences can be repeated in different techniques and different planes in order to achieve maximum information regarding small bowel wall and lumen, and high-quality imaging of extraintestinal complications as abscesses and fistulas may be obtained. Performing double bowel estimation with positive, followed by negative, contrast material during the same examination is possible, and there is also an option for imaging of small bowel peristalsis (functional examination).[@b7-ppa-10-1043]--[@b11-ppa-10-1043]

Alternatively, SBCE is the most sensitive method for assessing small bowel mucosa,[@b12-ppa-10-1043] and preliminary data suggest it has higher sensitivity and specificity for subtle small bowel lesions than MRE.[@b13-ppa-10-1043] However, it can only provide information concerning intraluminal disease.

Patient acceptability of a diagnostic procedure is a further important point to bear in mind when choosing between imaging modalities. This is especially true for patients with chronic disease who are increasingly required to undergo repeated and multiple examinations throughout their disease course. However, to the best of our knowledge, there is no data regarding the acceptability of MRE compared to CE. Better understanding of patients' preferences may improve compliance and lead to better disease management.

We therefore aimed to assess MRE and CE tolerability in CD patients.

Patients and methods
====================

This was an observational cohort study. The study population included adult (\>18 years) CD patients with known small bowel disease in remission or experiencing mild disease symptoms, as determined by the validated Crohn's disease activity index (CDAI) of \<150 or 150--220, respectively. In order to be included, patients had to be in corticosteroid-free remission for 3--24 months and were treated with a stable medication dose (60 days of thiopurines and methotrexate, 60 days of infliximab, and 30 days of adalimumab and aminosalicylate \[5-ASA\] agents).

Patients were excluded if they were unable to understand or provide informed consent; had severe comorbidities such as liver, kidney neurologic, metabolic, or cardiorespiratory disorders not controlled at the time of enrollment; had difficulty in swallowing, history of aspirations, or dysphagia; claustrophobia or implanted metal objects or cardiac pacemaker precluding performance of magnetic resonance imaging (MRI); or known or suspected intestinal obstruction or severe stricture.

All patients provided written informed consent, and the study was approved by the ethics committee of Chaim Sheba Medical Center, Tel HaShomer.

Patients were recruited between July 2013 and February 2015. MRE and video CE (VCE) were performed as part of the study protocol for meticulous disease follow-up. All patients included in the study underwent both procedures (MRE then VCE), with time difference between MRE to VCE of no more than 30 days. All patients underwent an MRE upon enrollment. All MRE examinations were performed using a 1.5T GE Optima MR450w scanner with GEM Suite (GE Healthcare, Little Chalfont, UK) with oral and intravenous contrast. Patients were asked to drink 1,000 mL of mannitol (5%) 60 minutes prior to the examination, followed by intravenous injection of glucagon (1 mg; GlucaGen^®^ HypoKit/Novo Nordisk A/S, Bagsværd, Denmark) and gadolinium (0.1 mmol/kg; gadoterate dimeglumine, Dotarem^®^, Guerbet, Villepinte, France). The MRE protocol included axial, coronal, and sagittal FIESTA (TR/TE 4.3/1.9 milliseconds); axial and coronal 2D SSFSE T2W (TR/TE 1,680--3,200/92.7 milliseconds); axial and coronal FSPGR FS BH (TR/TE 150/1.3 milliseconds); and coronal LAVA (TR/TE 4.2/2.1 milliseconds) pre- and postgadolinium injection. Field of view was 32--40 cm, with slice width 3.6--6 mm (previously described protocol).[@b14-ppa-10-1043]

A patency capsule (PC) test was performed in all patients with active small bowel disease detected on MRE. If no active small bowel disease was detected by MRE, a PC study was not performed. If a PC was not eliminated from the small bowel within 30 hours, the patients were withdrawn from the study. In patients with L1 disease by the Montreal classification, SB-III capsule (Given Imaging, Yokneam Illit, Israel) was used. In patients with established ileocolonic disease (L3 disease), a colonic capsule (PillCam colon2 capsule, Given Imaging) was administered.

The preparation for VCE included ingestion of only clear fluids for 24 hours prior to the procedure and a 12-hour overnight fast. For a colonic capsule study, a 4 L split-dose polyethylene glycol (PEG) preparation was used. An additional bolus with picosulfate (Pico-Salax^®^, Ferring, Germany) was given after the capsule reached the small bowel to facilitate small bowel transit, and another bolus was given 2 hours thereafter.

After completing each procedure, patients were asked to fill a questionnaire assessing their tolerance of MRE versus CE ([Figure S1](#SD1-ppa-10-1043){ref-type="supplementary-material"}). Specific assessment points included: inconvenience during preparation; inconvenience during the procedure; different side effects such as nausea, vomiting, bloating, abdominal pain, tenesmus, and claustrophobia during the examination; time needed to complete the examination; grade of exam's difficulty; and patients' consent to repeat the exam. Degree of severity was graded from 1 (not at all) to 5 (severe). Questionnaires were included for analysis only when more than 95% of the items were addressed.

Because different preparations were prescribed for colon capsule and for small bowel capsule, a separate subanalysis was also performed, whereby results were analyzed separately for each capsule category.

Statistical analysis
====================

Descriptive statistics were presented as mean ± standard deviation for continuous variables and percentages for categorical variables. Categorical variables were analyzed by chi-square/Fisher's exact test and continuous variables by Student's *t*-test/Mann--Whitney *U* test, as appropriate. *P*\<0.05 was considered significant. All computations were performed with the MedCalc Software (version 15.8; MedCalc, Mariakerke, Ostend, Belgium).

Results
=======

Of the 62 patients who were approached, 58 agreed to answer the questionnaire and 56 fulfilled inclusion criteria. Two patients were excluded because of incomplete data. Of these patients, 49 underwent SBCE and seven underwent colon CE. Patients' characteristics are shown in [Table 1](#t1-ppa-10-1043){ref-type="table"}.

Patient-reported scores for the main aspects of procedure tolerability are depicted in [Figure 1A--C](#f1-ppa-10-1043){ref-type="fig"}. For most parameters addressed, patients graded CE as significantly easier and more convenient than MRE. The average score for each modality and corresponding *P*-values are shown in [Table 2](#t2-ppa-10-1043){ref-type="table"}. CE was graded as significantly causing less discomfort before and during the exam, as well as causing less nausea, bloating, tinnitus, and abdominal pain. In addition, MRE was distinctive for causing claustrophobia in 16 patients (28.6%), which was naturally not observed in any of the CE procedures. Claustrophobia was never experienced by these patients before. Seventy-eight percent of patients (44 patients) preferred to repeat CE as compared to 22% (*P*\<0.0001) of patients who preferred MRE.

Overall, seven patients included in the study underwent colonic CE. Because precolonic capsule preparation is considered as relatively inconvenient, separate analysis was performed for colon capsule versus MRE ([Table 3](#t3-ppa-10-1043){ref-type="table"}) and for SBCE versus MRE ([Table 4](#t4-ppa-10-1043){ref-type="table"}).

Differing from patients who underwent SBCE, patients who underwent colonic CE tended to grade the discomfort during home preparation and before the exam as more severe than MRE (not statistically significant). Other factors such as nausea, vomiting, time consuming, and difficulty were graded as severe, as in MRE. Comparison between colonic CE and SBCE is shown in [Table 5](#t5-ppa-10-1043){ref-type="table"}. As shown in the table, pre-exam discomfort, nausea, and vomiting were significantly more severe in patients undergoing colonic CE. The examination was also considered as more time consuming and difficult than SBCE.

Nevertheless, five patients still preferred to repeat colonic CE, and three patients preferred MRE.

Discussion
==========

SBCE and MRE are both highly sensitive imaging modalities for the assessment of the small bowel of patients with CD. Although SBCE is the most sensitive modality for fine intraluminal lesion detection, MRE has the advantage of detecting extraluminal disease and complications.

In recent years, assessing disease's response to therapy and/or disease progression with consecutive bowel imaging has become the standard of care in many medical centers.[@b15-ppa-10-1043] Because patients are required to undergo repeated and frequent examinations, their acceptance and preference becomes an important issue to bear in mind. However, data in the literature are scarce.

In the present prospective study, patients who underwent both procedures significantly preferred CE to MRE. CE caused significantly less preprocedural and intraprocedural discomfort, less nausea and abdominal pain, and was considered as an easier procedure. Seventy-eight percent of patients preferred to repeat CE.

Unlike SBCE, colonic CE necessitates strict and prolonged preparation. Bowel preparation before colonic CE is highly intensive, as it requires ingestion of a 4 L split dose PEG as well as two boosters with Pico-Salax^®^. Many patients find this preparation difficult and inconvenient.

Thus, colonic CE showed no superiority over MRE when assessing patients' discomfort. SBCE showed significantly less pre-exam discomfort, and less nausea and vomiting than colonic CE. Furthermore, SBCE was graded as less time consuming and less difficult.

Interestingly, of the seven patients who underwent colonic CE, five still preferred to repeat the capsule, and two preferred MRE.

MRE is considered as an uncomfortable procedure.[@b16-ppa-10-1043]--[@b18-ppa-10-1043] Nausea and abdominal pain are the symptoms that were reported as contributing mostly to patients' inconvenience.[@b19-ppa-10-1043] A previous study addressed the issue of patients' acceptance of MRE,[@b19-ppa-10-1043] although comparison with CE was not performed. In this study, Negaard et al[@b19-ppa-10-1043] compared the acceptance of small bowel MRI with oral contrast material compared to magnetic resonance (MR) enteroclysis with nasogastric catheter. Not surprisingly, most patients preferred the oral ingestion of contrast material to the instillation through a nasogastric catheter. Both methods caused symptoms of nausea, vomiting, and abdominal pain. These side effects were reported by our patients as well. Other causes of patients' discomfort, such as claustrophobia or the prolonged duration of the procedure, which were reported by our patients, were not addressed in the prior study. Another study compared MR enteroclysis to SBCE and to double-balloon enteroscopy.[@b20-ppa-10-1043] In this study, the patient population included both patients with occult gastrointestinal bleeding and patients with suspected or known Crohn's disease. Similar to our results, CE was significantly preferred to MR enteroclysis and balloon-assisted enteroscopy with regard to bowel preparation, swallowing of the capsule (compared to insertion of the tube/scope), burden of the entire examination, duration, and accordance with the prestudy information. Other specific adverse effects of the procedures were not addressed.

Our study has a few limitations. First, only a small number of patients underwent colonic CE, and results of colon capsule subanalysis may be underpowered to detect differences. Nonetheless, it is noteworthy that the better overall tolerability of CE was demonstrated in the main analysis even when incorporating the results of colon CE patients. Moreover, 70% of colon CE patients still preferred to repeat colon CE to MRE. Another limitation is possible selection bias -- only patients who were willing to participate in a long-term follow-up study compelling repeated and frequent imaging, and blood and stool examinations were included. These patients may not be fully representative of the entire IBD population and may be more tolerant to medical procedures compared with patients who did not agree to participate in this CE/MRE prospective study. However, we speculate that patients who are less tolerant to medical procedures will have at least the same severity of side effects, if not worse.

Conclusion
==========

In our study, CE was significantly better tolerated than MRE in most parameters and preferred by 78% of patients. These observations should be borne in mind and integrated with the diagnostic yield and specific data being sought, when choosing the imaging modality for CD patients, in particular when repeated follow-up procedures are required.

Supplementary material
======================

###### 

Questionnaire -- post CE.

**Abbreviations:** CE, capsule endoscopy; MRE, magnetic resonance enterography.
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![Main procedures' tolerability parameters.\
**Notes:** (**A**) Pre-exam discomfort, *P*\<0.0001. (**B**) Discomfort during the exam, *P*\<0.0001. (**C**) Difficulty, *P*\<0.0001.\
**Abbreviation:** MRE, magnetic resonance enterography.](ppa-10-1043Fig1){#f1-ppa-10-1043}

###### 

Demographic data and disease characteristics

  ------------------------------------- -------
  Sex, n                                
   Female                               23
   Male                                 33
  Age (years), mean ± SD                32±11
  Disease duration (years), mean ± SD   6±5
  Disease location, n                   
   Small bowel disease                  53
   Small bowel + colonic disease        31
   Upper GI                             2
   Perianal disease                     8
  Previous CD-related surgery, n        10
  Clinical remission (CDAI \<150), n    49
  Current medications, n                
   Systemic corticosteroids             1
   Thiopurines                          26
   5-ASA                                8
   Anti-TNF                             24
  ------------------------------------- -------

**Abbreviations:** GI, gastrointestinal; CD, Crohn's disease; CDAI, Crohn's disease activity index; 5-ASA, aminosalicylate; TNF, tumor necrosis factor.

###### 

Tolerability to MRE versus CE

  Subject                         MRE (severity degree ± SD), N=56   CE (severity degree ± SD), N=56   *P*-value
  ------------------------------- ---------------------------------- --------------------------------- -----------
  Home preparation                2.38±1.32                          2.68±1.13                         0.1215
  Pre-exam discomfort             2.7±1.22                           1.5±0.99                          \<0.0001
  Discomfort during the exam      3.7±1.22                           2.0±1.08                          \<0.0001
  Nausea                          2.22±1.18                          1.29±0.53                         \<0.0001
  Vomiting                        1.5±1.05                           1.07±0.37                         0.009
  Bloating                        2.01±1.14                          1.25±0.55                         0.0002
  Abdominal pain                  2.24±1.1                           1.33±0.63                         \<0.0001
  Tenesmus                        1.40±0.87                          1.14±0.55                         0.0389
  Claustrophobia                  1.40±0.7                           1±0                               \<0.0001
  Time consuming                  3.46±1.19                          3.0±1.23                          0.0594
  Difficulty                      3.42±1.13                          2.03±0.98                         \<0.0001
  Drinking of contrast material   3.2±1.22                           NR                                NR

**Notes:** Score: 1= none to 5= severe. *P*-value: Mann--Whitney *U* test. *P*\<0.05 was considered significant.

**Abbreviations:** MRE, magnetic resonance enterography; CE, capsule endoscopy; NR, not relevant; SD, standard deviation.

###### 

Tolerability to MRE versus colonic CE

  Subject                         MRE (severity degree ± SD), N=7   Colon CE (severity degree ± SD), N=7   *P*-value
  ------------------------------- --------------------------------- -------------------------------------- -----------
  Home preparation                2.0±1.41                          3.57±1.49                              0.0916
  Pre-exam discomfort             3.14±1.12                         3.57±1.29                              0.4319
  Discomfort during the exam      3.28±1.03                         2.28±1.48                              0.1571
  Nausea                          2.14±1.12                         2.14±0.63                              0.8963
  Vomiting                        1.57±1.05                         1.57±0.9                               1.0000
  Bloating                        2.42±0.9                          1.42±0.49                              0.0474
  Abdominal pain                  2.0±0.53                          1.42±0.49                              0.0973
  Tenesmus                        1.71±1.16                         1.2±0.69                               0.5220
  Claustrophobia                  1.00±0                            1±0                                    1.0000
  Time consuming                  3.57±1.04                         4.0±0.75                               0.434
  Difficulty                      3.57±1.17                         3.0±1.41                               0.4793
  Drinking of contrast material   3.7±0.88                          NR                                     NR

**Notes:** Score: 1= none to 5= severe. *P*-value: Mann--Whitney *U* test. *P*\<0.05 was considered significant.

**Abbreviations:** MRE, magnetic resonance enterography; CE, capsule endoscopy; NR, not relevant; SD, standard deviation.

###### 

Tolerability to MRE versus SBCE

  Parameter                       MRE (severity degree ± SD), N=49   SBCE (severity degree ± SD), N=49   *P*-value
  ------------------------------- ---------------------------------- ----------------------------------- -----------
  Home preparation                2.41±1.30                          2.52±1.02                           0.4086
  Pre-exam discomfort             2.60±1.23                          1.22±0.46                           \<0.0001
  Discomfort during the exam      3.70±1.22                          1.93±1.00                           \<0.0001
  Nausea                          2.23±1.19                          1.66±0.37                           \<0.0001
  Vomiting                        1.48±1.04                          1.00±0.00                           0.0028
  Bloating                        1.93±1.16                          1.23±0.55                           0.0009
  Abdominal pain                  2.27±1.14                          1.31±0.65                           \<0.0001
  Tenesmus                        1.39±0.83                          1.16±0.59                           0.0648
  Claustrophobia                  1.45±0.73                          1±0                                 \<0.0001
  Time consuming                  3.42±1.12                          2.85±1.20                           0.0312
  Difficulty                      3.42±1.11                          1.87±0.80                           \<0.0001
  Drinking of contrast material   3.42±1.23                          NR                                  NR

**Notes:** Score: 1= none to 5= severe. *P*-value: Mann--Whitney *U* test. *P*\<0.05 was considered significant.

**Abbreviations:** MRE, magnetic resonance enterography; SBCE, small bowel capsule endoscopy; NR, not relevant; SD, standard deviation.

###### 

Tolerability to colonic CE versus SBCE

  Subject                      SBCE (severity degree ± SD), N=49   Colon CE (severity degree ± SD), N=7   *P*-value
  ---------------------------- ----------------------------------- -------------------------------------- -----------
  Home preparation             2.52±1.02                           3.57±1.49                              0.0721
  Pre-exam discomfort          1.22±0.46                           3.57±1.29                              \<0.0001
  Discomfort during the exam   1.93±1.00                           2.28±1.48                              0.7896
  Nausea                       1.66±0.37                           2.14±0.63                              0.0001
  Vomiting                     1.00±0.00                           1.57±0.9                               0.0021
  Bloating                     1.23±0.55                           1.42±0.49                              0.1666
  Abdominal pain               1.31±0.65                           1.42±0.49                              0.3482
  Tenesmus                     1.16±0.59                           1.2±0.69                               0.6408
  Claustrophobia               1±0                                 1±0                                    1.0000
  Time consuming               2.85±1.20                           4.0±0.75                               0.0189
  Difficulty                   1.87±0.80                           3.0±1.41                               0.0395

**Notes:** Score: 1= none to 5= severe. *P*-value: Mann--Whitney *U* test. *P*\<0.05 was considered significant.

**Abbreviations:** CE, capsule endoscopy; SBCE, small bowel capsule endoscopy; SD, standard deviation.

[^1]: These authors contributed equally to this work
